04 March 2022

Queensland Parliament

Brisbane

Queensland

Dear Committee,

1. I strongly disagree with any Extension of the Emergency Bill due to the prevalence of Omicron's extremely low death rate compared to the delta/alpha variants. Also, Queensland government fail to fully investigate the community evidence of COVID-19 vaccine injuries (Rennick 2022).

2. The original Emergency Bill was granted based on past death rates from the Alpha and Delta variants of COVID-19 infections. However, the Omicron is contagious but with very low mortality rates. Also, it is important for Queensland government to use all the four pillars of Pandemic controls strategies. These four pillars are (Greenhalgh et al. 2014; Gupta et al. 2020; Nkengasong 2020; Shrivastava & Shrivastava 2020; Stoecklin et al. 2020; Awadasseid et al. 2021; Bansal et al. 2021; López-Medina et al. 2021; Pott-Junior et al. 2021; Santin et al. 2021; Pan et al. 2022):

   A] Contagious control
   B] Early home treatment
   C] Hospital treatment
   D] Vaccines

   Particularly, it is important for the government to focus on Early home treatment according to peer-reviewed literature evidence. Otherwise, it is poor pandemic management to mainly focus on COVID-19 vaccines, with no evidence of longitudinal studies about safety, and effectiveness. Also, I argue it is poor risk management without proper investigations on the COVID-19 vaccine injuries.

1

3. Case numbers of COVID-19 infections have indicated that the original modelling was greatly exaggerated. This is important because new COVID-19 variants would create new clinical challenges and new patterns of disease behaviours (Samrat et al. 2020).

4. The extension of Emergency Bill is based on COVID-19 deaths in Queensland and COVID-19 numbers. But it is important to differentiate deaths with COVID-19, and COVID-19 deaths that have comorbidity. These differences are important in clinical diagnosis. To know the real deaths due to COVID-19, and deaths due to other causes that associate with COVID-19 infections (comorbidity)

Moreover, ADE (Arvin et al. 2020; Bournazos et al. 2020; Karthik et al. 2020; Wen et al. 2020; Ricke 2021; Sánchez-Zuno et al. 2021; Wang & Zand 2021) and Immunopathology (Khade et al. 2021; Rawat et al. 2021; Shahgolzari et al. 2021; Su et al. 2021; van Eijk et al. 2021) are important in COVID-19 vaccine injuries. Thus. it is crucial for Queensland health to provide peer-reviewed literature evidence about Antibody Dependent Enhancement (ADE), and Immunopathology in COVID-19 vaccines. It is also important for Queensland health to provide independent clinical audit on the potential impacts of ADE, and Immunopathology in the COVID-19 vaccines.

5. The health data inherit evidence of exaggeration. For example, the health data lacks credibility when Queensland government, Queensland hospitals, and Australian Health Practitioner Regulation Agency stops healthcare staff from exposing COVID-19 vaccine injuries. Queensland government, Queensland hospitals, and Australian Health Practitioner Regulation Agency will not collect the true data about the risks, and COVID-19 injuries when Queensland government, Queensland hospitals, and Australian Health Practitioner Regulation Agency gag staff from exposing COVID-19 vaccine injuries.

6. Current estimates indicate that Omicron deaths are only a very small fraction of those adjusted numbers. Any extension is not warranted and should NOT be granted.

7. The Emergency Bill already create medical apartheid, discrimination, and segregations in our societies. Also, the Queensland government and hospitals stop the healthcare workers from exposing the COVID-19 vaccine injuries. Even the Australian Health

2

Practitioner Regulation Agency (AHPRA) threatened to deregister staff who expose the COVID-19 vaccine injuries. Such practices show that Queensland government, Queensland hospitals, and AHPRA are hiding the evidence of COVID-19 vaccine injuries from the public.

8. The negative impacts of these mandates and the pressure it is imposing on people of Queenslanders through lost jobs and a pressured healthcare system, will cause more problems if the Emergency Bill continues. Particularly when it seems that many Queenslanders have had COVID-19, now have natural immunity, and according to the Government's own modelling the peak has now passed.

Yours sincerely

Rosie Sisiolo

List of References

Arvin, AM, Fink, K, Schmid, MA, Cathcart, A, Spreafico, R, Havenar-Daughton, C, Lanzavecchia, A, Corti, D & Virgin, HW 2020, 'A perspective on potential antibody-dependent enhancement of SARS-CoV-2', *Nature*, vol. 584, no. 7821, pp. 353-63.

Awadasseid, A, Wu, Y, Tanaka, Y & Zhang, W 2021, 'Current advances in the development of SARS-CoV-2 vaccines', *International Journal of Biological Sciences*, vol. 17, no. 1, p. 8.

Bansal, P, Goyal, A, Cusick IV, A, Lahan, S, Dhaliwal, HS, Bhyan, P, Bhattad, PB, Aslam, F, Ranka, S & Dalia, T 2021, 'Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019', *Annals of Medicine*, vol. 53, no. 1, pp. 117-34.

Bournazos, S, Gupta, A & Ravetch, JV 2020, 'The role of IgG Fc receptors in antibody-dependent enhancement', *Nature Reviews Immunology*, vol. 20, no. 10, pp. 633-43.

Greenhalgh, T, Howick, J & Maskrey, N 2014, 'Evidence based medicine: a movement in crisis?', *Bmj*, vol. 348.

Gupta, S, Hayek, SS, Wang, W, Chan, L, Mathews, KS, Melamed, ML, Brenner, SK, Leonberg-Yoo, A, Schenck, EJ & Radbel, J 2020, 'Factors associated with death in critically ill patients with coronavirus disease 2019 in the US', *JAMA internal medicine*, vol. 180, no. 11, pp. 1436-47.

Karthik, K, Senthilkumar, TMA, Udhayavel, S & Raj, GD 2020, 'Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19', *Human vaccines & immunotherapeutics*, vol. 16, no. 12, pp. 3055-60.

Khade, SM, Yabaji, SM & Srivastava, J 2021, 'An update on COVID-19: SARS-CoV-2 life cycle, immunopathology, and BCG vaccination', *Preparative biochemistry & biotechnology*, vol. 51, no. 7, pp. 650-8.

4

López-Medina, E, López, P, Hurtado, IC, Dávalos, DM, Ramirez, O, Martínez, E, Díazgranados, JA, Oñate, JM, Chavarriaga, H & Herrera, S 2021, 'Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial', *JAMA*, vol. 325, no. 14, pp. 1426-35.

Nkengasong, J 2020, 'China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response', *Nature medicine*, vol. 26, no. 3, pp. 310-1.

Pan, L, Wang, J, Wang, X, Ji, JS, Ye, D, Shen, J, Li, L, Liu, H, Zhang, L & Shi, X 2022, 'Prevention and control of coronavirus disease 2019 (COVID-19) in public places', *Environmental Pollution*, vol. 292, p. 118273.

Pott-Junior, H, Paoliello, MMB, Miguel, AdQC, da Cunha, AF, de Melo Freire, CC, Neves, FF, de Avó, LRdS, Roscani, MG, Dos Santos, SDS & Chachá, SGF 2021, 'Use of ivermectin in the treatment of Covid-19: a pilot trial', *Toxicology reports*, vol. 8, pp. 505-10.

Rawat, K, Kumari, P & Saha, L 2021, 'COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies', *European journal of pharmacology*, vol. 892, p. 173751.

Rennick, G 2022, viewed February 28, 2022, <https://www.facebook.com/gerard.rennick>.

Ricke, DO 2021, 'Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies', *Frontiers in immunology*, p. 443.

Samrat, SK, Tharappel, AM, Li, Z & Li, H 2020, 'Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development', *Virus research*, p. 198141.

Sánchez-Zuno, GA, Matuz-Flores, MG, González-Estevez, G, Nicoletti, F, Turrubiates-Hernández, FJ, Mangano, K & Muñoz-Valle, JF 2021, 'A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies', *International journal of immunopathology and pharmacology*, vol. 35, p. 20587384211050199.

Santin, AD, Scheim, DE, McCullough, PA, Yagisawa, M & Borody, TJ 2021, 'Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with

indicated efficacy against a new global scourge, COVID-19', *New microbes and new infections*, vol. 43, p. 100924.

Shahgolzari, M, Yavari, A, Arjeini, Y, Miri, SM, Darabi, A, Nejad, ASM & Keshavarz, M 2021, 'Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn', *Gene Reports*, vol. 25, p. 101417.

Shrivastava, SR & Shrivastava, PS 2020, 'Lessons learned from China's response to coronavirus disease 2019 pandemic and implications for the rest of the world', *Journal of Nature and Science of Medicine*, vol. 3, no. 4, p. 366.

Stoecklin, SB, Rolland, P, Silue, Y, Mailles, A, Campese, C, Simondon, A, Mechain, M, Meurice, L, Nguyen, M & Bassi, C 2020, 'First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020', *Eurosurveillance*, vol. 25, no. 6, p. 2000094.

Su, S, Du, L & Jiang, S 2021, 'Learning from the past: development of safe and effective COVID-19 vaccines', *Nature Reviews Microbiology*, vol. 19, no. 3, pp. 211-9.

van Eijk, LE, Binkhorst, M, Bourgonje, AR, Offringa, AK, Mulder, DJ, Bos, EM, Kolundzic, N, Abdulle, AE, van der Voort, PH & Olde Rikkert, MG 2021, 'COVID-19: immunopathology, pathophysiological mechanisms, and treatment options', *The Journal of pathology*, vol. 254, no. 4, pp. 307-31.

Wang, J & Zand, MS 2021, 'The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development', *Journal of Clinical and Translational Science*, vol. 5, no. 1.

Wen, J, Cheng, Y, Ling, R, Dai, Y, Huang, B, Huang, W, Zhang, S & Jiang, Y 2020, 'Antibody-dependent enhancement of coronavirus', *International Journal of Infectious Diseases*, vol. 100, pp. 483-9.

6